Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06925724 · ClinicalTrials.gov registry record · Phase 2

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

A Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
7
Study locations

NCT06925724: Recruiting Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06925724 is a Phase 2 study of Endometrial Cancer and Cervical Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06925724, a Phase 2 study of Endometrial Cancer and Cervical Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
7
Study locations

Study Summary

The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

Primary Outcome

Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Interventions

  • DRUG Ivonescimab

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-04-04
Est. Completion 2027-04-04
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT06925724 shows while recruiting

NCT06925724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ivonescimab is the first listed.

NCT06925724 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT06925724 about?

NCT06925724 is a clinical study titled "A Study of Ivonescimab in People With Endometrial and Cervical Cancers". The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

What is the current status of trial NCT06925724?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-04-04. Estimated completion is 2027-04-04.

What conditions does trial NCT06925724 study?

This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer.

What interventions are being tested in trial NCT06925724?

The interventions under investigation include: Ivonescimab (DRUG).

Who is sponsoring clinical trial NCT06925724?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06925724 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06925724's enrollment target sits among peer trials

50 125th of 181 higher than 54 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06925724, the US trial registry maintained by the National Library of Medicine. NCT06925724 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.